Endoscopic hemostatic powder spray: Current evidence and clinical applications

Table 3 Regional availability of hemostatic powders used in gastrointestinal bleeding, European Conformity

Product (manufacturer, origin)	Region(s) where marketed	Notes
TC-325 (Hemospray®; Cook Medical, United States)	United States, Canada, Europe, and other regions	Approved for endoscopic hemostasis in non-variceal upper GI bleeding; CE marking also reported for pediatric use
EndoClot® Polysaccharide Hemostatic System (EndoClot Plus, United States)	Europe, Türkiye, Malaysia, Australia	Country-level availability varies; no product-specific approval data identified for other regions
Ankaferd Blood Stopper® (ABS; AND Pharmaceuticals, Türkiye)	Türkiye (predominantly); limited availability elsewhere	Reported by the manufacturer as the first original locally licensed hemostatic medicinal product in Türkiye
UI-EWD (NexPowder™; Next Biomedical, Republic of Korea)	Republic of Korea, United States, Europe	FDA-cleared since 2022; most clinical evidence originates from Korean cohorts
CEGP-003 (CG Bio, Republic of Korea)	Republic of Korea	Availability and regulatory status outside the Republic of Korea not reported
Self-propelling thrombin powder (experimental agent)	None	Preclinical animal studies only
Polysaccharide hemostatic powder (multiple products)	China, Republic of Korea	Regulatory status differs according to the specific product

Regulatory information was compiled from the open United States Food and Drug Administration 510(k) database, manufacturer information, and published reviews. European Conformity marking is required for marketing in the European Union where a product is reported as marketed in Europe. “None” indicates that no reliable information was identified in the reviewed sources. ABS: Ankaferd Blood Stopper; CE: European Conformity; FDA: United States Food and Drug Administration; GI: Gastrointestinal.